Results 1 to 10 of about 40,516 (197)

Burden of Typical Diseases Attributed to the Sources of PM2.5-Bound Toxic Metals in Beijing: An Integrated Approach to Source Apportionment and QALYs

Environment International, 2019
PM2.5-bound toxic metals (TMs) are derived from various sources, and they can cause many adverse health effects on the human body. To effectively reduce the disease burden of TMs by controlling the relative sources, an integrated approach of quality ...
Jianwei Liu, Hongbin Cao, Aichen Zhang
exaly   +3 more sources

Cost-effectiveness of pembrolizumab plus weekly paclitaxel for PD-L1–positive platinum-resistant recurrent ovarian cancer in the United States and China [PDF]

Frontiers in Pharmacology
BackgroundPembrolizumab plus weekly paclitaxel, with or without bevacizumab, improves survival in programmed death ligand 1 (PD-L1)–positive platinum-resistant recurrent ovarian cancer, but its economic value remains uncertain.
Feng Xuan, Haoze Bian, Minguang Huang, Yan Yang, Guodong Wang   +4 more
doaj   +2 more sources

Extracorporeal carbon dioxide removal compared to ventilation alone in patients with acute hypoxaemic respiratory failure: cost-utility analysis of the REST RCT

Health Technology Assessment, 2023
Background Acute hypoxaemic respiratory failure requiring mechanical ventilation is a major cause of morbidity and mortality and has significant resource implications in terms of intensive care unit and hospital stay.
Ashley Agus, James J. McNamee, Colette Jackson, Danny F. McAuley   +3 more
doaj   +1 more source

The estimated disease burden of COVID-19 in Japan from 2020 to 2021

Journal of Infection and Public Health, 2023
Background: To date, it is not fully understood to what extent COVID-19 has burdened society in Japan. This study aimed to estimate the total disease burden due to COVID-19 in Japan during 2020–2021.
Shinya Tsuzuki, Philippe Beutels
doaj   +1 more source

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma

Frontiers in Oncology, 2022
BackgroundIn this study, compared to sunitinib as one of the available treatment options, we aimed to evaluate the cost-effectiveness of lenvatinib plus pembrolizumab or everolimus as first-line treatment for advanced renal cell carcinoma (RCC) patients ...
Ye Wang, Hao Wang, Manman Yi, Zhou Han, Li Li   +4 more
doaj   +1 more source

The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER)

INNOVATIONS in Pharmacy, 2020
All too often organizations embrace standards for health technology assessment that fail to meet the standards of normal science. A continuing puzzle is why the axioms of fundamental measurement are ignored by researchers such as the University of ...
Paul Langley
doaj   +1 more source

Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis

Thrombosis Journal, 2021
Background Recently, direct oral anticoagulants (DOACs) have been included in guidelines for the treatment of cancer-associated thrombosis (CAT) to be extended to suitable cancer patients.
Kaidireyahan Wumaier, Wenqian Li, Naifei Chen, Jiuwei Cui   +3 more
doaj   +1 more source

Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemic-A cost-effectiveness analysis.

PLoS ONE, 2022
Background and aimCOVID-19 pandemic burdens the healthcare systems, causes healthcare avoidance, and might worsen the outcomes of inflammatory bowel disease (IBD) management. We aimed to estimate the impact of pandemic-related avoidance on outpatient IBD
Jiaqi Yao, Ginenus Fekadu, Xinchan Jiang, Joyce H S You   +3 more
doaj   +1 more source

Quality-adjusted life years for digital cognitive behavioural therapy for insomnia (Sleepio): a secondary analysis

BJGP Open, 2022
Background: Insomnia is common, and difficulty with daytime functioning is a core symptom. Studies show cognitive behavioural therapy (CBT) improves functioning, but evidence is needed on its value for money.
Elizabeth A Stokes, Richard Stott, Alasdair L Henry, Colin A Espie, Christopher B Miller   +4 more
doaj   +1 more source

Personal and societal health quality lost to tuberculosis.

PLoS ONE, 2009
BackgroundIn developed countries, tuberculosis is considered a disease with little loss of Quality-Adjusted Life Years (QALYs). Tuberculosis treatment is predominantly ambulatory and death from tuberculosis is rare.
Thaddeus L Miller, Scott J N McNabb, Peter Hilsenrath, Jotam Pasipanodya, Stephen E Weis   +4 more
doaj   +1 more source